W
REGN icon

WealthCollab’s Regeneron Pharmaceuticals REGN Stock Holding History

WealthCollab’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$3.09K – 1045
2026
Q1 		$3.09K Hold
4
– – ﹤0.01% 780
2025
Q4 		$3.09K Hold
4
– – ﹤0.01% 822
2025
Q3 		$2.25K Hold
4
– – ﹤0.01% 814
2025
Q2 		$2.1K Sell
4
-16
-80% -$8.93K ﹤0.01% 805
2025
Q1 		$12.7K Sell
20
-29
-59% -$19.9K 0.01% 411
2024
Q4 		$34.9K Hold
49
– – 0.02% 211
2024
Q3 		$51.5K Sell
49
-25
-34% -$27.8K 0.03% 156
2024
Q2 		$77.8K Hold
74
– – 0.06% 115
2024
Q1 		$71.2K Hold
74
– – 0.05% 120
2023
Q4 		$65K Buy
+74
New +$60.9K 0.05% 118

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

WealthCollab's REGN Position: Q2 2026 in Review

WealthCollab sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 4 shares — an estimated $3.09K sold.

WealthCollab first reported a position in REGN in Q4 2023 and held it in 10 quarters. The position peaked at $77.8K in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • WealthCollab reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • WealthCollab sold 4 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.09K.
  • WealthCollab first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 10 quarters.
  • WealthCollab's Regeneron Pharmaceuticals position peaked at $77.8K in Q2 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on WealthCollab's 13F filing for Q2 2026, filed 10 Aug 2026.